Abstract
Infliximab, a chimeric (humanized mouse) monoclonal antibody which specifically inhibits TNF-alpha, has recently shown efficacy in the treatment of refractory sarcoidosis. The manifestations of sarcoidosis are diverse; however, the long-term effects on the lungs are often the most life-threatening. We describe a patient with sarcoidosis who experienced the complete resolution of her cutaneous disease and stabilization of her pulmonary symptoms after initiation of infliximab.
Original language | English (US) |
---|---|
Pages (from-to) | 413-414 |
Number of pages | 2 |
Journal | Journal of drugs in dermatology : JDD |
Volume | 2 |
Issue number | 4 |
State | Published - Aug 2003 |
Externally published | Yes |
ASJC Scopus subject areas
- General Medicine